Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation therapy in children.

Shoshana Revel-Vilk1, Anthony K C Chan

  • 1Pediatric Hematology/ Oncology Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Seminars in Thrombosis and Hemostasis
|October 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Enhanced Antithrombogenic Performance of Microfluidic Oxygenators through Dual Bioactive Surface Modification for an Artificial Placenta System.

Acta biomaterialia·2026
Same author

Individual Comparative PK Evaluation of Single-dose Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Adults with Severe Hemophilia A.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Case Report: Atypical presentations of neonatal and infantile hemophilia B.

Frontiers in pediatrics·2026
Same author

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease.

International journal of molecular sciences·2026
Same author

Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams.

Pediatric blood & cancer·2026
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Pediatric thromboembolic events (TEs) are rare but serious, especially in vulnerable children. Differences in hemostasis impact treatment responses, necessitating pediatric-specific anticoagulant research.

Area of Science:

  • Pediatric Hematology
  • Thrombosis and Hemostasis

Background:

  • Thromboembolic events (TEs) are increasingly recognized causes of morbidity and mortality in children.
  • Children with serious conditions like congenital heart disease or cancer, and neonates, infants, and adolescents are at higher risk.
  • Central venous lines and intra-arterial catheters are significant risk factors for pediatric TEs.

Purpose of the Study:

  • To examine the impact of the developmental hemostatic system on anticoagulant responses in children.
  • To highlight the differences between pediatric and adult hemostasis and their implications for thrombosis and treatment.

Main Methods:

  • Review of current literature on pediatric thromboembolism.
  • Analysis of hemostatic differences between pediatric and adult populations.

Related Experiment Videos

  • Evaluation of commonly used anticoagulants in children (unfractionated heparin, low-molecular-weight heparins, warfarin).

    • Main Results:

    • Pediatric hemostasis differs significantly from adult hemostasis, affecting thrombotic processes and anticoagulant efficacy.
    • Established anticoagulant therapies in children are often extrapolated from adult studies.
    • Limited experience exists with novel antithrombotic agents in pediatric populations.

    Conclusions:

    • Optimal anticoagulant therapy for pediatric thromboembolism requires further investigation.
    • Well-designed prospective trials are essential to establish evidence-based treatment guidelines for children.
    • Addressing the unique hemostatic characteristics of children is crucial for effective TEs management.